JNJ · News · 20260913N

Oncology Pipeline Progress

JOHNSON & JOHNSON · 2026-09-13 · Importance 34 · Surprise 42

Johnson & Johnson reported final overall-survival results from the Phase 3 PAPILLON study of first-line intravenous RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy in advanced non-small-cell lung cancer. The study enrolled patients with EGFR exon 20 insertion mutations and compared the combination with chemotherapy alone. The company said the combination delivered the longest reported median overall survival for this patient population, which has a historical five-year survival rate of approximately 8%.

Key facts

• Johnson & Johnson announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutations. source
• Johnson & Johnson stated that RYBREVANT plus chemotherapy "delivers longest reported median overall survival" in EGFR exon 20 insertion mutation-positive lung cancer. source
• Johnson & Johnson stated RYBREVANT plus chemotherapy "demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET." source
• The press release noted the patient population has a historical five-year survival rate of just 8%. source
• The press release was dated SEOUL, South Korea, Sept. 13, 2026. source
• The company described RYBREVANT by its USAN/identifier as amivantamab-vmjw. source